|
|
Article: Signase Plans Growth On Src Kinase Family Platform.(Company overview)
- Article from:
- BIOWORLD Today
- Article date:
- November 4, 2009
CopyrightCOPYRIGHT 2009 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Staff Writer
Signase is coming into its own with an emphasis on the Src kinase family.
By focusing on the discovery and development of inhibitors of protein tyrosine kinases, Houston-based Signase hopes to find applications not only in cancer, but also in osteoporosis, regulating immune function and central nervous system disorders.
The company was founded in 1997 but operated at the M.D. Anderson Cancer Center, using grant money to fund its research efforts, said Signase CEO David McWilliams, who came on board in May. Before Signase, McWilliams spent 10 years with Texas Biotechnology Corp., also of Houston, as its president and CEO.
...